1655 related articles for article (PubMed ID: 21304082)
1. Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis: a randomized clinical trial.
Giuliano AE; Hunt KK; Ballman KV; Beitsch PD; Whitworth PW; Blumencranz PW; Leitch AM; Saha S; McCall LM; Morrow M
JAMA; 2011 Feb; 305(6):569-75. PubMed ID: 21304082
[TBL] [Abstract][Full Text] [Related]
2. Effect of Axillary Dissection vs No Axillary Dissection on 10-Year Overall Survival Among Women With Invasive Breast Cancer and Sentinel Node Metastasis: The ACOSOG Z0011 (Alliance) Randomized Clinical Trial.
Giuliano AE; Ballman KV; McCall L; Beitsch PD; Brennan MB; Kelemen PR; Ollila DW; Hansen NM; Whitworth PW; Blumencranz PW; Leitch AM; Saha S; Hunt KK; Morrow M
JAMA; 2017 Sep; 318(10):918-926. PubMed ID: 28898379
[TBL] [Abstract][Full Text] [Related]
3. Locoregional Recurrence After Sentinel Lymph Node Dissection With or Without Axillary Dissection in Patients With Sentinel Lymph Node Metastases: Long-term Follow-up From the American College of Surgeons Oncology Group (Alliance) ACOSOG Z0011 Randomized Trial.
Giuliano AE; Ballman K; McCall L; Beitsch P; Whitworth PW; Blumencranz P; Leitch AM; Saha S; Morrow M; Hunt KK
Ann Surg; 2016 Sep; 264(3):413-20. PubMed ID: 27513155
[TBL] [Abstract][Full Text] [Related]
4. Locoregional recurrence after sentinel lymph node dissection with or without axillary dissection in patients with sentinel lymph node metastases: the American College of Surgeons Oncology Group Z0011 randomized trial.
Giuliano AE; McCall L; Beitsch P; Whitworth PW; Blumencranz P; Leitch AM; Saha S; Hunt KK; Morrow M; Ballman K
Ann Surg; 2010 Sep; 252(3):426-32; discussion 432-3. PubMed ID: 20739842
[TBL] [Abstract][Full Text] [Related]
5. A 10-year follow-up of treatment outcomes in patients with early stage breast cancer and clinically negative axillary nodes treated with tangential breast irradiation following sentinel lymph node dissection or axillary clearance.
Wernicke AG; Goodman RL; Turner BC; Komarnicky LT; Curran WJ; Christos PJ; Khan I; Vandris K; Parashar B; Nori D; Chao KS
Breast Cancer Res Treat; 2011 Feb; 125(3):893-902. PubMed ID: 20853176
[TBL] [Abstract][Full Text] [Related]
6. Surgical complications associated with sentinel lymph node dissection (SLND) plus axillary lymph node dissection compared with SLND alone in the American College of Surgeons Oncology Group Trial Z0011.
Lucci A; McCall LM; Beitsch PD; Whitworth PW; Reintgen DS; Blumencranz PW; Leitch AM; Saha S; Hunt KK; Giuliano AE;
J Clin Oncol; 2007 Aug; 25(24):3657-63. PubMed ID: 17485711
[TBL] [Abstract][Full Text] [Related]
7. Survival analysis of early-stage breast cancer patients undergoing axillary lymph node dissection and sentinel lymph node dissection.
Nayyar A; Strassle PD; Shen MR; Black JA; Gallagher KK; McGuire KP
Am J Surg; 2018 Oct; 216(4):706-712. PubMed ID: 30060915
[TBL] [Abstract][Full Text] [Related]
8. Impact of the american college of surgeons oncology group Z0011 criteria applied to a contemporary patient population.
Yi M; Kuerer HM; Mittendorf EA; Hwang RF; Caudle AS; Bedrosian I; Meric-Bernstam F; Wagner JL; Hunt KK
J Am Coll Surg; 2013 Jan; 216(1):105-13. PubMed ID: 23122536
[TBL] [Abstract][Full Text] [Related]
9. Sentinel-lymph-node resection compared with conventional axillary-lymph-node dissection in clinically node-negative patients with breast cancer: overall survival findings from the NSABP B-32 randomised phase 3 trial.
Krag DN; Anderson SJ; Julian TB; Brown AM; Harlow SP; Costantino JP; Ashikaga T; Weaver DL; Mamounas EP; Jalovec LM; Frazier TG; Noyes RD; Robidoux A; Scarth HM; Wolmark N
Lancet Oncol; 2010 Oct; 11(10):927-33. PubMed ID: 20863759
[TBL] [Abstract][Full Text] [Related]
10. Sentinel node skills verification and surgeon performance: data from a multicenter clinical trial for early-stage breast cancer.
Posther KE; McCall LM; Blumencranz PW; Burak WE; Beitsch PD; Hansen NM; Morrow M; Wilke LG; Herndon JE; Hunt KK; Giuliano AE
Ann Surg; 2005 Oct; 242(4):593-9; discussion 599-602. PubMed ID: 16192820
[TBL] [Abstract][Full Text] [Related]
11. Comparison of survival outcomes between axillary conservation and axillary lymph node dissections in N1 early breast cancer: a propensity-matched SEER analysis.
Wu N; Su X; Tan Q; Luo J; Yuan Y; Hou L; Li J
Clin Transl Oncol; 2023 Apr; 25(4):1091-1101. PubMed ID: 36515887
[TBL] [Abstract][Full Text] [Related]
12. Improved axillary staging of breast cancer with sentinel lymphadenectomy.
Giuliano AE; Dale PS; Turner RR; Morton DL; Evans SW; Krasne DL
Ann Surg; 1995 Sep; 222(3):394-9; discussion 399-401. PubMed ID: 7677468
[TBL] [Abstract][Full Text] [Related]
13. Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with node-positive breast cancer: the ACOSOG Z1071 (Alliance) clinical trial.
Boughey JC; Suman VJ; Mittendorf EA; Ahrendt GM; Wilke LG; Taback B; Leitch AM; Kuerer HM; Bowling M; Flippo-Morton TS; Byrd DR; Ollila DW; Julian TB; McLaughlin SA; McCall L; Symmans WF; Le-Petross HT; Haffty BG; Buchholz TA; Nelson H; Hunt KK;
JAMA; 2013 Oct; 310(14):1455-61. PubMed ID: 24101169
[TBL] [Abstract][Full Text] [Related]
14. When is a lymph node dissection a lymph node dissection? The number of lymph nodes resected in sentinel and axillary lymph node dissections.
Olaya W; Wong J; Wong J; Morgan J; Kazanjian K; Lum S
Ann Surg Oncol; 2013 Feb; 20(2):627-32. PubMed ID: 22956069
[TBL] [Abstract][Full Text] [Related]
15. Retrospectively validating the results of the ACOSOG Z0011 trial in a large Asian Z0011-eligible cohort.
Jung J; Han W; Lee ES; Jung SY; Han JH; Noh DY; Kim Y; Choi HJ; Lee JE; Nam SJ; Lee JW; Kim HJ; Um E; Kim JH; Park S; Cho YU
Breast Cancer Res Treat; 2019 May; 175(1):203-215. PubMed ID: 30715659
[TBL] [Abstract][Full Text] [Related]
16. Tailored axillary surgery with or without axillary lymph node dissection followed by radiotherapy in patients with clinically node-positive breast cancer (TAXIS): study protocol for a multicenter, randomized phase-III trial.
Henke G; Knauer M; Ribi K; Hayoz S; Gérard MA; Ruhstaller T; Zwahlen DR; Muenst S; Ackerknecht M; Hawle H; Fitzal F; Gnant M; Mátrai Z; Ballardini B; Gyr A; Kurzeder C; Weber WP
Trials; 2018 Dec; 19(1):667. PubMed ID: 30514362
[TBL] [Abstract][Full Text] [Related]
17. [Optimal treatment of the axilla after positive sentinel lymph node biopsy in early invasive breast cancer. Early results of the OTOASOR trial].
Sávolt A; Musonda P; Mátrai Z; Polgár C; Rényi-Vámos F; Rubovszky G; Kovács E; Sinkovics I; Udvarhelyi N; Török K; Kásler M; Péley G
Orv Hetil; 2013 Dec; 154(49):1934-42. PubMed ID: 24292111
[TBL] [Abstract][Full Text] [Related]
18. Sentinel lymph node dissection provides axillary control equal to complete axillary node dissection in breast cancer patients with lobular histology and a negative sentinel node.
Khakpour N; Hunt KK; Kuerer HM; Yi M; Meric-Bernstam F; Ross MI; Lucci A
Am J Surg; 2005 Oct; 190(4):598-601. PubMed ID: 16164930
[TBL] [Abstract][Full Text] [Related]
19. Management of the Axilla in T1-2 Breast Cancer Patients with Macrometastatic Sentinel Node Involvement Who Underwent Breast-Conserving Therapy.
Kuru B; Yuruker S; Sullu Y; Gursel B; Ozen N
J Invest Surg; 2019 Jan; 32(1):48-54. PubMed ID: 28945489
[TBL] [Abstract][Full Text] [Related]
20. Impact of axillary dissection in women with invasive breast cancer who do not fit the Z0011 ACOSOG trial because of three or more metastatic sentinel lymph nodes.
Bonneau C; Hequet D; Estevez JP; Pouget N; Rouzier R
Eur J Surg Oncol; 2015 Aug; 41(8):998-1004. PubMed ID: 25986854
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
